Outcomes
redness, uveitis, pain, haze, floaters
ADVERSE EVENTS, UVEITIS, DECREASED VISION, SECONDARY, DISEASES
The primary outcome was the time to worsening of symptomatic uveitis, defined by 1 of the following new-onset symptoms occurring in at least 1 eye and lasting for at least 2 days: eye redness, eye pain, decreased vision, light sensitivity, or floaters, as confirmed by blinded review by an adjudication committee. The adjudication committee consisted of 3 independent clinicians, and the outcome was achieved with a majority of 2. Key secondary outcomes included proportion of COVID-19 vaccination, proportion of adherence to recommendation, proportion of each worsening symptom, proportion of 2-grade increase in anterior chamber cells from baseline to month 3, proportion of 2-grade increase in vitreous haze from baseline to month 3, change in BCVA from baseline to month 3, and incidence of systemic adverse events. The original protocol also included secondary outcomes concerning clinically confirmed uveitis worsening, hospitalization, and treatment, which were determined based on in-person clinical evaluation when patients returned to the study site or visited local hospitals with symptomatic uveitis worsening. During the execution of the trial, most cases with worsening symptoms did not seek medical services and assessment at our study center, nor did they provide medical records to show their local hospital visits, possibly due to their mild diseases, self-care, remote living, or COVID-19 travel restrictions. Therefore, these secondary outcomes were not reported in terms of data unavailability.